World’s first discovery of the molecular mechanisms of violet light for myopia: Violet light suppresses myopia progression via the non-visual photoreceptor, OPN5.
Major milestone in exploratory clinical trial for a medical device: Confirmation of the suppressive effect of violet light on myopia progression
Case Report of Axial Length Shortening in a High Myopic Child After Wearing Violet Light-Transmitting Eyeglasses
A major step in the development of a medical device for the suppression of myopia progression Safety was confirmed in the exploratory clinical trial
Our comments on the press release for the “Kubota Glasses” Developed by Kubota Pharmaceutical Holdings Co., Ltd.
We will join 2020 BIO International Convention Digital.
We have a booth at "JAPAN INNOVATION DAY 2020 by ASCII STARTUP!” on March 19!
We were selected as a participant in the "IP Acceleration program for Startups (IPAS)" of Japan Patent Office for this fiscal year.
We won the third prize in the "2019 International Science and Technology Innovation and Entrepreneurship Competition" held in Wuhan, Hubei Province, China. The participants were startups from the US, UK, Japan, France, Canada and Singapore, and presented their new technologies and business models.
We were selected as a recipient of a NEDO grant for Seed-stage Technology-based Startups (STS) for this fiscal year.
“Myopia Crisis” featured on NHK Broadcasting
We were selected as a recipient of the "Strategic IP Overseas Expansion Grant" of Organization for Small & Medium Enterprises and Regional Innovation, Japan for this fiscal year.
We are conducting a clinical trial with our eyeglasses-type medical device for myopic grade school children aged from 6 to 12.
The paper on current prevalence on myopia was published on JAMA OPHTHALMOLOGY.